Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $19.66, but opened at $18.53. Enliven Therapeutics shares last traded at $22.16, with a volume of 772,304 shares.

Wall Street Analyst Weigh In

ELVN has been the topic of a number of recent analyst reports. HC Wainwright boosted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th.

Enliven Therapeutics Stock Performance

The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.53 and a beta of 0.79. The business has a fifty day moving average of $18.18 and a two-hundred day moving average of $20.68.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at $490,590. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now owns 990,392 shares of the company's stock, valued at $20,629,865.36. This trade represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 101,111 shares of company stock worth $1,936,664 in the last ninety days. 25.90% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

Several large investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of Enliven Therapeutics by 3.2% during the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after purchasing an additional 199,692 shares in the last quarter. Polar Capital Holdings Plc grew its holdings in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in shares of Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after purchasing an additional 135,969 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.